Abstract
Purpose
Patients with neuroendocrine neoplasms (NEN) engage in lifelong follow-up with frequent somatostatin receptor PET, e.g. [64Cu]Cu-DOTATATE PET, and continued measures to reduce radiation exposures should be in pursued in accordance with the as-low-as-reasonably-achievable (ALARA) principle. We therefore aimed to determine the lowest achievable [64Cu]Cu-DOTATATE dose while maintaining image quality and lesion detection rate.
Procedures
We included scans from 38 patients with NEN referred to routine [64Cu]Cu-DOTATATE PET/CT. Using reconstruction of under-sampled PET list-mode data, we simulated [64Cu]Cu-DOTATATE activity dose-reduced PET equivalents with median [range] 142 MBq [127;157], 95 MBq [85;105], and 48 MBq [42;52], corresponding to 75% (PET75%), 50% (PET50%), and 25% (PET25%) of the full-dose 191 MBq [169;209] (PET100%). Three blinded readers independently assessed image quality (scores 1–5), lesion confidence (scores 0–2), and counted lesions grouped by organs and regions. Number of lesions, proportions of patients with diagnostic image quality (reader-median image quality ≥ 4), diagnostic lesion confidence (reader-median lesion confidence ≥ 1), and per-patient sensitivities and specificities for organ-specific disease on PET75-25% were compared with PET100%.
Results
The median [64Cu]Cu-DOTATATE activity dose could be reduced from 191 to 142 MBq without decline in diagnostic image quality (P = 0.62), diagnostic lesion confidence (P = 1.0), or number of lesions detected in major organs or regions (P = 0.19–0.71). Sensitivity and specificity for detection of liver disease were 100% (26/26 patients) and 100% (12/12), respectively, for both PET75% and PET50%. Overall sensitivity for detection of NEN was 100% (26/26) for both PET75% and PET50%, and overall specificities were 92% (11/12) and 100% (12/12) for PET75 and PET50, respectively. Following dose-blinded post hoc review, the PET75% specificity was adjusted to 100% (12/12).
Conclusions
The [64Cu]Cu-DOTATATE activity dose can be reduced from 191 MBq to at least 142 MBq without losing image quality or lesion detection ability and further reduced to 95 MBq without loss of clinically relevant information.
Similar content being viewed by others
References
Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in The United States. J Clin Oncol 26:3063–3072
Reubi JC (2004) Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 80(Suppl 1):51–56
Bozkurt MF, Virgolini I, Balogova S et al (2017) Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur J Nucl Med Mol Imaging 44:1588–1601
Janson ET, Knigge U, Dam G et al (2021) Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol 60:931–941
Knigge U, Capdevila J, Bartsch DK et al (2017) ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms: follow-up and documentation. Neuroendocrinology 105:310–319
Strosberg JR, Halfdanarson TR, Bellizzi AM et al (2017) The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas 46:707–714
ICRP (2007) Radiological protection in medicine. Ann ICRP 37:1–63
Dasari A, Shen C, Halperin D et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335–1342
Cao LL, Lu J, Lin JX et al (2018) Incidence and survival trends for gastric neuroendocrine neoplasms: an analysis of 3523 patients in the SEER database. Eur J Surg Oncol 44:1628–1633
Johnbeck CB, Knigge U, Loft A et al (2017) Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med 58:451–457
Pfeifer A, Knigge U, Binderup T et al (2015) 64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients. J Nucl Med 56:847–854
Pfeifer A, Knigge U, Mortensen J et al (2012) Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med 53:1207–1215
Johnbeck CB, Knigge U, Kjaer A (2014) PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol 10:2259–2277
Delpassand ES, Ranganathan D, Wagh N et al (2020) 64Cu-DOTATATE PET/CT for imaging patients with known or suspected somatostatin receptor-positive neuroendocrine tumors: results of the first U.S. prospective, reader-masked clinical trial. J Nucl Med 61:890–896
Conti M, Eriksson L (2016) Physics of pure and non-pure positron emitters for PET: a review and a discussion. Ejnmmi Phys 3:8
Orange Book: approved drug products with therapeutic equivalence evaluations. U.S. Food and Drug Administration website. Detectnet Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213227s000lbl.pdf. Accessed 7 Jan 2022
Orange Book: approved drug products with therapeutic equivalence evaluations. U.S. Food and Drug Administration website. Netspot Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208547s000lbl.pdf. Accessed 7 Jan 2022
Orange Book: approved drug products with therapeutic equivalence evaluations. U.S. Food and Drug Administration website. Ga 68 Dotatoc Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210828s002lbl.pdf. Accessed 7 Jan 2022
Loft M, Carlsen EA, Johnbeck CB et al (2021) 64Cu-DOTATATE PET in patients with neuroendocrine neoplasms: prospective, head-to-head comparison of imaging at 1 hour and 3 hours after injection. J Nucl Med 62:73–80
Carlsen EA, Johnbeck CB, Binderup T et al (2020) 64Cu-DOTATATE PET/CT and prediction of overall and progression-free survival in patients with neuroendocrine neoplasms. J Nucl Med 61:1491–1497
Carlsen EA, Johnbeck CB, Loft M et al (2021) Semi-automatic tumor delineation for evaluation of 64Cu-DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume. J Nucl Med 62:1564–1570
Hope TA (2020) Updates to the appropriate-use criteria for somatostatin receptor PET. J Nucl Med 61:1764
National Comprehensive Cancer Network (2021) Neuroendocrine and adrenal tumors (Version 4.2021). https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed 7 Jan 2022
Gatidis S, Wurslin C, Seith F et al (2016) Towards tracer dose reduction in PET studies: Simulation of dose reduction by retrospective randomized undersampling of list-mode data. Hell J Nucl Med 19:15–18
van Sluis J, Boellaard R, Dierckx R et al (2020) Image quality and activity optimization in oncologic 18F-FDG PET using the digital biograph vision PET/CT system. J Nucl Med 61:764–771
Loft M, Johnbeck CB, Carlsen EA et al (2021) Initial experience with 64Cu-DOTATATE digital PET of patients with neuroendocrine neoplasms: comparison with analog PET. Diagnostics 11:350
Pantel AR, Viswanath V, Daube-Witherspoon ME et al (2020) PennPET Explorer: Human imaging on a whole-body imager. J Nucl Med 61:144–151
Virgolini I, Bahri S, Kjaer A et al (2021) A randomised, factorial phase II study to determine the optimal dosing regimen for 68Ga-satoreotide trizoxetan as an imaging agent in patients with gastroenteropancreatic neuroendocrine tumours. J Nucl Med. https://doi.org/10.2967/Jnumed.121.261936
Funding
This project received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreements no. 670261 (ERC Advanced Grant) and 668532 (Click-It), the Lundbeck Foundation, the Novo Nordisk Foundation, the Innovation Fund Denmark, the Danish Cancer Society, Arvid Nilsson Foundation, the Neye Foundation, the Research Foundation of Rigshospitalet, the Danish National Research Foundation (grant 126), the Research Council of the Capital Region of Denmark, the Danish Health Authority, the John and Birthe Meyer Foundation, and the Research Council for Independent Research. Andreas Kjaer is a Lundbeck Foundation Professor.
Author information
Authors and Affiliations
Contributions
Conceptualization: M.L., C.B.J., E.A.C., F.L.A., and A.K.; formal analysis: M.L., C.B.J., E.A.C., and A.K.; investigation: M.L., C.B.J., E.A.C., and C.V.J.; methodology: M.L., C.B.J., E.A.C., C.V.J., F.L.A., and A.K.; resources: P.O., S.W.L., F.L.A., U.K., and A.K.; software: C.V.J.; supervision: U.K. and A.K.; visualization: M.L.; writing—original draft preparation: M.L.; writing—review and editing: all authors. All authors have read and agreed to the final version of the manuscript.
Corresponding author
Ethics declarations
Ethical Approval
This research study was conducted retrospectively in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards following approval by the Danish Patient Safety Authority (Ref 31–1521-453) according to Danish regulations. For this type of study, formal consent is not required. All the procedures being performed were part of the patient’s routine care.
Conflict of Interest
U.K. and A.K. are inventors/holds intellectual property rights on a patent covering [64Cu]Cu-DOTATATE. All other authors declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Loft, M., Carlsen, E.A., Johnbeck, C.B. et al. Activity Dose Reduction in 64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Impact on Image Quality and Lesion Detection Ability. Mol Imaging Biol 24, 600–611 (2022). https://doi.org/10.1007/s11307-022-01706-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-022-01706-4